An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

…, SW Mason, S Noell, JJ Novak, RS Obach, K Ogilvie… - Science, 2021 - science.org
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral …

[HTML][HTML] Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

…, RS Obach, MN O'Brien, R O'Connor, K Ogilvie… - Nature …, 2021 - nature.com
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease
is a virally encoded protein that is essential across a broad spectrum of coronaviruses with …

Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19

…, RS Obach, MN O'Brien, R O'Connor, K Ogilvie… - BioRxiv, 2020 - biorxiv.org
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease
is a virally encoded protein that is essential to the viral life cycle across a broad spectrum of …

A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl) ethoxyl] methyl] guanine, highly active in vitro against herpes simplex virus types 1 and 2

…, KS Galloway, WL Kennell, KK Ogilvie… - Antimicrobial agents …, 1982 - Am Soc Microbiol
A novel nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-guanine (BIOLF-62),
was found to have potent antiviral activity against herpes simplex virus types 1 and 2 at …

Directed ortho Metalation−Boronation and Suzuki−Miyaura Cross Coupling of Pyridine Derivatives:  A One-Pot Protocol to Substituted Azabiaryls

M Alessi, AL Larkin, KA Ogilvie, LA Green… - The Journal of …, 2007 - ACS Publications
A general method for the synthesis of azabiaryls 19a−t by a one-pot procedure involving a
Directed ortho metalation (DoM)−boronation−Suzuki−Miyaura cross coupling sequence is …

Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug–drug interactions with a novel series of centrally efficacious BACE1 inhibitors

…, P Mikochik, JC Murray, K Ogilvie… - Journal of medicinal …, 2015 - ACS Publications
In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical
development for the treatment of Alzheimer’s disease (AD). However, the alignment of drug-…

Discovery of the potent and selective MC4R antagonist PF-07258669 for the potential treatment of appetite loss

…, R O'Connor, K Ogilvie… - Journal of Medicinal …, 2023 - ACS Publications
The melanocortin-4 receptor (MC4R) is a centrally expressed, class A GPCR that plays a key
role in the regulation of appetite and food intake. Deficiencies in MC4R signaling result in …

Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: Utilization of structure based drug design, watermap, and CNS …

MA Brodney, G Barreiro, K Ogilvie… - Journal of medicinal …, 2012 - ACS Publications
β-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention
of Alzheimer’s disease (AD). Herein, we describe the discovery of a novel class of BACE-1 …

Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design

…, JK Dutra, LA Martinez-Alsina, K Ogilvie… - Journal of medicinal …, 2015 - ACS Publications
The identification of centrally efficacious β-secretase (BACE1) inhibitors for the treatment of
Alzheimer’s disease (AD) has historically been thwarted by an inability to maintain alignment …

Design and synthesis of clinical candidate PF-06751979: a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor lacking …

…, A Villalobos, JC Murray, K Ogilvie… - Journal of Medicinal …, 2018 - ACS Publications
A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1
(BACE1) inhibitors for the treatment of Alzheimer’s disease is the alignment of potency, drug…